Tuesday, March 31, 2009
Spaltudaq Becomes Theraclone Sciences
Seattle-based Spaltudaq, a developer of human antibodies for the treatment of influenza, HIV, and human cytomegalovirus, said Monday that the firm has changed its name to Theraclone Sciences. The firm said the new name "highlights our ability to clone and express clinically relevant, naturally fully human antibodies for clinical and commercial benefit." The company is backed by ARCH Venture Partners, Canaan Partners and Healthcare Ventures. The announcement came as it announced that it has identified two new antibodies that may neutralize HIV.